Enstilar

Generic name: Calcipotriene And Betamethasone Dipropionate
Dosage form: foam
Drug class: Topical antipsoriatics

Usage of Enstilar

Enstilar foam is a once-daily, topical, fixed-dose combination foam containing Calcipotriene 0.005% (a vitamin D analog) and Betamethasone dipropionate 0.064% (a corticosteroid) that may be used to treat plaque psoriasis in adults and children 12 years of age or older.

Enstilar foam is a stable supersaturated solution of calcipotriol/Betamethasone dipropionate that has improved clinical efficacy and increased skin penetration compared with standard calcipotriol/betamethasone dipropionate ointments.

Enstilar was approved on October 16, 2015.

Enstilar side effects

The most common side effects reported with Enstilar include irritation or itch at the application site, folliculitis, skin hypopigmentation, high calcium levels, urticaria, and exacerbation of psoriasis.

Postmarketing studies with topical corticosteroids have reported atrophy, striae, telangiectasias, itching, dryness, hypopigmentation, perioral dermatitis, secondary infection, and miliaria.

Ophthalmic adverse reactions of cataracts, glaucoma, and increased intraocular pressure, have been reported during the use of topical corticosteroids, including topical betamethasone products.

Before taking Enstilar

You should not use Enstilar foam if you are allergic to calcipotriene, betamethasone dipropionate, or any other components of the foam.

Tell your doctor if you have ever had:

too much calcium in your blood or urine

an adrenal gland disorder

cataracts or glaucoma

liver disease

severe forms of psoriasis (with pus, skin peeling, severe redness)

have thinning skin at the treatment site

a skin infection or

if you are receiving UV light treatments (phototherapy).

Pregnancy

The use of high-potency topical steroid medicine during pregnancy may increase the risk of a low birth weight in the newborn baby. Tell your doctor if you are pregnant or plan to become pregnant.

Lactation

It may not be safe to breastfeed while using Enstilar. Ask your doctor about any risks. If you apply Betamethasone and calcipotriene to your chest, avoid areas that may come into contact with the baby's mouth.

Relate drugs

How to use Enstilar

Enstilar should be applied once daily to the plaques for up to 4 weeks.

Shake the can before applying the foam.

Hold the can 1.5 inches (one and a half inches) away from the affected areas and spray the foam onto the plaques by pushing down on the nozzle, in any position except sideways.

Gently rub in the foam until it is absorbed. After applying, put the cap back on the can and you’re your hands.

Discontinue treatment once control has been achieved.

Do not use more than 60 grams every 4 days.

Do not apply an occlusive dressing over the top of Enstilar foam unless directed by a physician.

Do not use it on your face, groin, or armpit, or if skin thinning is present at the treatment site.

Not for oral, ophthalmic, or intravaginal use.

The contents of the Enstilar can are flammable and you should avoid being near sources of fire or flames, or smoking, immediately following application.

Warnings

Use only as directed. Tell your doctor if you use other medicines or have other medical conditions or allergies.

Hypercalcemia and hypercalciuria have been observed with the use of topical calcipotriene. If either occurs, discontinue Enstilar foam until laboratory values of calcium normalize.

Endocrine effects

The use of high-potency steroid products such as betamethasone dipropionate can cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency during and after withdrawal of treatment. Risk factors include the use of high-potency topical corticosteroids, use over a large surface area, or to areas under occlusion, prolonged use, altered skin barrier, liver failure, and young age. Modify use of Enstilar foam should HPA axis suppression develop.

Ophthalmic Adverse Reactions

May increase the risk of cataracts and glaucoma. If visual symptoms occur, consider referral to an ophthalmologist.

Allergic contact dermatitis

May occur with either calcipotriene or betamethasone dipropionate topical use. May be observed as a failure to heal. Confirm with diagnostic patch testing.

Children

Children can absorb larger amounts of this medicine through the skin and may be more likely to have side effects. Enstilar foam is not approved for use by anyone younger than 12 years old.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.